Neurocrine Biosciences (NBIX) FY2017 results: revenue $162 million, up 977.5% on the year
Neurocrine Biosciences Inc. (NBIX) reported revenue of $162 million for fiscal 2017, the year ended 31 December 2017, up 977.5% on the year before. Net income was -$143 million, and diluted earnings per share $-1.62. The figures are the company's own, from the 10-K it filed with the SEC on 13 February 2018.
Revenue
$162 million
+977.5% on the year
FY2010FY2017
Operating margin
-81.3%
-982.5% a year earlier
FY2010FY2017
Net income
-$143 million
FY2010FY2017
Diluted EPS
-$1.62
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
162
15.0
19.8
+977.5%
Cost of revenue
1.3
0.0
0.0
Gross profit
160
15.0
19.8
+969.1%
Gross margin
99.2%
100.0%
100.0%
Research and development
122
94.3
81.5
+29.2%
Selling, general and administrative
170
68.1
32.5
+149.6%
Operating income
-131
-147
-94.2
Operating margin
-81.3%
-982.5%
-476.5%
Interest expense
19.5
0.0
0.0
Pre-tax income
-143
-141
n/a
Income tax
0.0
0.0
0.0
Net income
-143
-141
-88.9
Net margin
-88.2%
-940.6%
-449.8%
Diluted EPS
-$1.62
-$1.63
-$1.05
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
-94.3
-106
-38.0
Capital expenditure
6.9
4.1
1.9
+68.9%
Free cash flow
-101
-110
-39.9
Free cash flow margin
-62.7%
-735.3%
-202.0%
Cash from investing
-251
113
n/a
Cash from financing
517
2.4
n/a
+21,517.0%
Depreciation and amortisation
2.4
1.5
1.0
+65.2%
Share-based compensation
42.5
28.5
28.4
+49.4%
Diluted shares, weighted
88m
87m
84m
+1.6%
Shares outstanding at period end
89m
87m
86m
+2.2%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
372
315
424
+18.2%
Debt
370
0.0
0.0
Other liabilities
75.8
50.2
50.3
+51.0%
Total liabilities and equity
818
365
475
+123.9%
Fixed assets
10.8
6.3
3.4
+72.4%
Investments
509
268
387
+90.1%
Cash and equivalents
255
83.3
74.2
+205.9%
Receivables
31.1
0.0
n/a
Inventory
1.0
0.0
n/a
Other assets
11.3
8.0
9.7
+42.2%
Total assets
818
365
475
+123.9%
10-K for the year ended 31 December 2017, filed 13 February 2018: the filing.